Vaccine immunogenetics: Bedside to bench to population

Vaccine

Volumn 26, Issue 49, 2008, Pages 6183-6188

  Poland, Gregory A ^a   Ovsyannikova, Inna G ^b   Jacobson, Robert M ^c  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Vaccine Research Group   (United States)

^c Mayo Clinic   (United States)

Author keywords

CD46; Cytokines; Genetic association; HLA; Measles vaccine; Polymorphisms; SLAM; TLR

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; TOLL LIKE RECEPTOR; VACCINE; VIRUS RECEPTOR; VIRUS VACCINE;

ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; ECONOMIC ASPECT; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENETICS; MEASLES VIRUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CYTOKINES; HLA ANTIGENS; HUMANS; IMMUNITY; IMMUNOGENETICS; MEASLES VACCINE; POLYMORPHISM, GENETIC; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTORS; TWIN STUDIES AS TOPIC; VACCINES;

EID: 55549106096     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.057     Document Type: Article

References (56)

1. Centers for Disease Control and Prevention. Ten Great Public Health Achievements, United States, 1900-1999. MMWR 1999; 48, No. 12 (April):241-64.
2. CDC's 60th anniversary: director's perspective-William L, Roper MD, MPH, 1990-1993. MMWR Morb Mortal Wkly Rep 2007; 56(18):448-52.
3. Bunker J.P., Frazier H.S., and Mosteller F. Improving health: measuring effects of medical care. Milbank Q 72 2 (1994) 225-258
4. Alper C.A., Kruskall M.S., Marcus-Bagley D., Craven D.E., Katz A.J., Brink S.J., et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321 (1989) 708-712
5. Poland G.A., Ovsyannikova I.G., Jacobson R.M., and Smith D.I. Heterogeneity in vaccine immune response: The role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82 6 (2007) 653-664
6. Spielberg S.P. Therapeutics and toxicology. Curr Opin Pediatr 10 (1998) 201-202
7. Poland G.A., and Jacobson R.M. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch Intern Med 154 (1994) 1815-1820
8. Poland G.A. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet 62 (1998) 215-220
9. Tan P.-L., Jacobson R.M., Poland G.A., Jacobsen S.J., and Pankratz S.V. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 19 (2001) 2434-2439
10. Grote D., Russell S.J., Cornu T.I., Cattaneo R., Vile R., Poland G.A., et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97 (2001) 3746-3754
11. Peng K.W., Frenzke M., Myers R., Soeffker D., Harvey M., Greiner S., et al. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 14 16 (2003) 1565-1577
12. Jacobson R.M., Ovsyannikova I.G., Targonski P.V., and Poland G.A. Studies of twins in vaccinology. Vaccine 25 16 (2007) 3160-3164
13. Poland G.A., and Jacobson R.M. The genetic basis for variation in antibody response to vaccines. Curr Opin Pediatr 10 (1998) 208-215
14. Jacobson R.M., Poland G.A., Vierkant R.A., Pankratz V.S., Schaid D.J., Jacobsen S.J., et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum Immunol 64 1 (2003) 103-109
15. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20 3-4 (2001) 430-438
16. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz S.V., Jacobsen S.J., and Poland G.A. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22 (2004) 1914-1920
17. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz V.S., and Poland G.A. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: Findings and implications for vaccine design. Vaccine 25 16 (2007) 3090-3100
18. Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., and Poland G.A. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 193 5 (2006) 655-663
19. Ovsyannikova I.G., Jacobson R.M., Ryan J.E., Vierkant R.A., Pankratz V.S., and Poland G.A. Human Leukocyte Antigen and Interleukin 2, 10 and 12p40 cytokine responses to measles: Is there evidence of the HLA effect?. Cytokine 36 (2006) 173-179
20. Ovsyannikova I.G., Ryan J.E., Vierkant R.A., Pankratz S.V., Jacobson R.M., and Poland G.A. Immunologic significance of HLA class I genes in measles virus-specific IFN-gamma and IL-4 cytokine immune responses. Immunogenetics 57 11 (2005) 828-836
21. Ovsyannikova I.G., Jacobson R.M., Ryan J.E., Vierkant R.A., Pankratz V.S., Jacobsen S.J., et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56 (2005) 798-807
22. St. Sauver J.L., Ovsyannikova I.G., Jacobson R.M., Jacobsen S.J., Vierkant R.A., Schaid D.J., et al. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J Infect Dis 185 11 (2002) 1545-1549
23. Poland G.A., Jacobson R.M., Thampy A.M., Colbourne S.A., Wollan P.C., Lipsky J.J., et al. Measles re-immunization in children seronegative after initial immunization. JAMA 277 (1997) 1156-1158
24. St. Sauver J.L., Dhiman N., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz V.S., et al. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. Hum Immunol 66 (2005) 788-798
25. Kruskall M.S. The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med 63 (1990) 477-486
26. Ovsyannikova I.G., Dhiman N., Jacobson R.M., Vierkant R.A., Pankratz V.S., and Poland G.A. HLA homozygosity does not adversely effect measles vaccine-induced cytokine responses. Virology 364 1 (2007) 87-94
27. Ovsyannikova I.G., Jacobson R.M., and Poland G.A. Variation in vaccine response in normal populations. Pharmacogenomics 5 4 (2004) 417-427
28. Ovsyannikova I.G., Dhiman N., Jacobson R.M., and Poland G.A. Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Exp Rev Vacc 5 1 (2006) 33-43
29. Poland G.A., Ovsyannikova I.G., and Jacobson R.M. Genetic influences on the immune response to vaccines. In: Kaslow R.A., McNicholl J.M., and Hill A.V.S. (Eds). Genetic susceptibility to infectious diseases (2008), Oxford University Press, New York 414-429
30. Dorig R.E., Marcil A., Chopra A., and Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75 2 (1993) 295-305
31. Tatsuo H., Ono N., Tanaka K., and Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406 6798 (2000) 893-897
32. Dhiman N., Jacobson R.M., and Poland G.A. Measles virus receptors: SLAM and CD46. Rev Med Virol 14 4 (2004) 217-229
33. Dhiman N., Cunningham J.M., Jacobson R.M., Vierkant R.A., Wu Y., Ovsyannikova I.G., et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol 120 3 (2007) 666-672
34. van Deventer S.J.H. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 26 Suppl. 1 (2000) S98-S102
35. Biron C.A. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 6 (1994) 530-538
36. Dhiman N., Ovsyannikova I.G., Cunningham J.M., Vierkant R.A., Kennedy R.B., Pankratz V.S., et al. Associations between measles vaccine immunity and single nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195 (2007) 21-29
37. Pravica V., Asderakis A., Perrey C., Hajeer A., Sinnott P.J., and Hutchinson I.V. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 26 1 (1999) 1-3
38. Tanabe M., Kurita-Taniguchi M., Takeuchi K., Takeda M., Ayata M., Ogura H., et al. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 311 1 (2003) 39-48
39. Heinz S., Haehnel V., Karaghiosoff M., Schwarzfischer L., Muller M., Krause S.W., et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278 24 (2003) 21502-21509
40. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301 5633 (2003) 640-643
41. tenOever B.R., Servant M.J., Grandvaux N., Lin R., and Hiscott J. Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation. J Virol 76 8 (2002) 3659-3669
42. Bieback K., Lien E., Klagge I.M., Avota E., Schneider-Schaulies J., Duprex W.P., et al. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 76 17 (2002) 8729-8736
43. Hahm B., Cho J.H., and Oldstone M.B. Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: Selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology 358 2 (2006) 251-257
44. Dhiman N., Ovsyannikova I.G., Vierkant R.A., Ryan J.E., Pankratz V.S., Jacobson R.M., et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26 (2008) 1731-1736
45. Schroder N.W., and Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5 3 (2005) 156-164
46. Tal G., Mandelberg A., Dalal I., Cesar K., Somekh E., Tal A., et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189 11 (2004) 2057-2063
47. Hill A.V. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 40 (2006) 469-486
48. Chanock S.J., Manolio T., Boehnke M., Boerwinkle E., Hunter D.J., Thomas G., et al. Replicating genotype-phenotype associations. Nature 447 7145 (2007) 655-660
49. Poland GA. Personalized vaccines: from populations to persons. Exp Opin Biol Ther; in press.
50. Stanley Jr. S.L., Frey S.E., Taillon-Miller P., Buo J., Miller R.D., Koboldt D.C., et al. The immunogenetics of smallpox vaccination. J Infect Dis 196 2 (2007) 212-219
51. Ovsyannikova I.G., Johnson K.L., Bergen III H.R., and Poland G.A. Mass spectrometry and peptide-based vaccine development. Clin Pharmacol Ther 82 6 (2007) 644-652
52. Siber G.R., Santosham M., Reid G.R., Thompson C., Almeido-Hill J., Morell A., et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 323 (1990) 1387-1392
53. Ward J., Brenneman G., Letson G.W., Heyward W.L., and The Alaska H. Influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 323 (1990) 1393-1401
54. Santosham M., Rivin B., Wolff M., Reid R., Newcomer W., Letson G.W., et al. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children. J Infect Dis 165 Suppl. 1 (1992) S144-S151
55. Black F.L., Hierholzer W., Woodall J.P., and Pinhiero F. Intensified reactions to measles vaccine in unexposed populations of American Indians. J Infect Dis 124 (1971) 306-317
56. Hinman A.R., Orenstein W.A., and Rodewald L. Financing immunizations in the United States. Clin Infect Dis 38 10 (2004) 1440-1446